JAK1 and COVID-19: Three FDA-approved drugs for other indications were repurposed for COVID-19 treatment: Baricitinib, Ruxolitonib, and Tofacitinib, which target JAK1/JAK2, JAK1/JAK2, and JAK1/JAK3, respectively [39].